DNLI - Denali Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

DNLI is currently covered by 11 analysts with an average price target of $34.2. This is a potential upside of $14.7 (67.81%) from yesterday's end of day stock price of $20.38.

Denali Therapeutics's activity chart (see below) currently has 178 price targets and 158 ratings on display. The stock rating distribution of DNLI is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 30.16% with an average time for these price targets to be met of 109.23 days.

Highest price target for DNLI is $42, Lowest price target is $23, average price target is $34.2.

Most recent stock forecast was given by MAYANK MAMTANI from B. RILEY on 25-Aug-2026. First documented stock forecast 02-Jan-2018.

Best performing analysts who are covering DNLI - Denali Therapeutics:

Christopher Marai Andrew Fein Michael Yee Matthew Harrison Salveen Richter Tazeen Ahmad

Currently out of the existing stock ratings of DNLI, 22 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 06-Sep-2023

$35

$13.91 (65.96%)

$35

21 days ago
(25-Aug-2026)

0/3 (0%)

$10.07 (40.39%)

Buy Since 03-Jan-2018

$36

$14.91 (70.70%)

$35

1 months 23 days ago
(23-Jul-2026)

3/16 (18.75%)

$12.58 (53.71%)

389

Buy Since 13-Dec-2023

$35

$13.91 (65.96%)

$31

1 months 30 days ago
(16-Jul-2026)

1/5 (20%)

$12.27 (53.98%)

208

Buy Since 02-Jan-2018

$29

$7.91 (37.51%)

$26

2 months 2 days ago
(13-Jul-2026)

6/9 (66.67%)

$2.52 (9.52%)

199

Buy Since 07-Aug-2025

$39

$13.43 (52.52%)

$36

4 months 4 days ago
(11-May-2026)

1/7 (14.29%)

$19.33 (98.27%)

40

Show more analysts

Please expand the browser size to see the chart

What is DNLI (Denali Therapeutics) average time for price targets to be met?

On average it took 109 days for the stock forecasts to be reached, with an average price target met ratio of 30.16%.

Which analyst most recently updated their price target on DNLI (Denali Therapeutics)?

Mayank Mamtani

Which analyst has the most public recommendations on DNLI (Denali Therapeutics)?

Mayank Mamtani works at B. RILEY and has 4 price targets and 3 ratings on DNLI

Which analyst is the currently most bullish on DNLI (Denali Therapeutics)?

Esther Rajavelu with the highest potential upside of $50.77

Which analyst is the currently most reserved on DNLI (Denali Therapeutics)?

Laura Chico with the lowest potential downside of -$2.57

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?